JP6764021B2 - ナイセリア・メニンギティディスのワクチン - Google Patents

ナイセリア・メニンギティディスのワクチン Download PDF

Info

Publication number
JP6764021B2
JP6764021B2 JP2019511860A JP2019511860A JP6764021B2 JP 6764021 B2 JP6764021 B2 JP 6764021B2 JP 2019511860 A JP2019511860 A JP 2019511860A JP 2019511860 A JP2019511860 A JP 2019511860A JP 6764021 B2 JP6764021 B2 JP 6764021B2
Authority
JP
Japan
Prior art keywords
polysaccharide
vaccine
conjugate
carrier protein
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526573A5 (OSRAM
JP2019526573A (ja
Inventor
リチャード・デイヴィッド・ケンシンガ−
スティーヴン・エル・ハウザー
Original Assignee
サノフィ パスツール インコーポレイテッド
サノフィ パスツール インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ パスツール インコーポレイテッド, サノフィ パスツール インコーポレイテッド filed Critical サノフィ パスツール インコーポレイテッド
Publication of JP2019526573A publication Critical patent/JP2019526573A/ja
Publication of JP2019526573A5 publication Critical patent/JP2019526573A5/ja
Application granted granted Critical
Publication of JP6764021B2 publication Critical patent/JP6764021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019511860A 2016-09-02 2017-09-01 ナイセリア・メニンギティディスのワクチン Active JP6764021B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662383279P 2016-09-02 2016-09-02
US62/383,279 2016-09-02
US201762468695P 2017-03-08 2017-03-08
US62/468,695 2017-03-08
US201762505525P 2017-05-12 2017-05-12
US62/505,525 2017-05-12
PCT/US2017/049856 WO2018045286A1 (en) 2016-09-02 2017-09-01 Neisseria meningitidis vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020150938A Division JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン

Publications (3)

Publication Number Publication Date
JP2019526573A JP2019526573A (ja) 2019-09-19
JP2019526573A5 JP2019526573A5 (OSRAM) 2020-05-14
JP6764021B2 true JP6764021B2 (ja) 2020-09-30

Family

ID=59846741

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019511860A Active JP6764021B2 (ja) 2016-09-02 2017-09-01 ナイセリア・メニンギティディスのワクチン
JP2020150938A Active JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン
JP2022021720A Active JP7329087B2 (ja) 2016-09-02 2022-02-16 ナイセリア・メニンギティディスのワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020150938A Active JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン
JP2022021720A Active JP7329087B2 (ja) 2016-09-02 2022-02-16 ナイセリア・メニンギティディスのワクチン

Country Status (24)

Country Link
US (4) US11147866B2 (OSRAM)
EP (2) EP4309670A3 (OSRAM)
JP (3) JP6764021B2 (OSRAM)
KR (2) KR20190044663A (OSRAM)
CN (2) CN109890413B (OSRAM)
AU (2) AU2017321863B2 (OSRAM)
BR (1) BR112019003992A2 (OSRAM)
CA (1) CA3033364A1 (OSRAM)
DK (1) DK3506935T3 (OSRAM)
ES (1) ES2974992T3 (OSRAM)
FI (1) FI3506935T3 (OSRAM)
HR (1) HRP20240433T1 (OSRAM)
HU (1) HUE066007T2 (OSRAM)
LT (1) LT3506935T (OSRAM)
MX (1) MX2019002489A (OSRAM)
PH (1) PH12019500399B1 (OSRAM)
PL (1) PL3506935T3 (OSRAM)
PT (1) PT3506935T (OSRAM)
RS (1) RS65362B1 (OSRAM)
SA (1) SA519401227B1 (OSRAM)
SG (1) SG11201901394XA (OSRAM)
SI (1) SI3506935T1 (OSRAM)
WO (1) WO2018045286A1 (OSRAM)
ZA (1) ZA201901402B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101359953B1 (ko) * 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
JP2023503086A (ja) 2019-11-22 2023-01-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌サッカリド複合糖質ワクチンの用法及び用量
MX2023009728A (es) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Vacuna recombinante meningococica b.
US20250249086A1 (en) 2022-04-11 2025-08-07 Sanofi Pasteur Inc. Protein-Saccharide Conjugation with Sodium Cyanoborohydride
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
JP2024075506A (ja) * 2022-11-22 2024-06-03 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5097020A (en) 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
CA2142981C (en) * 1992-08-31 2007-10-23 Joseph Y. Tai Vaccines against group c neisseria meningitidis
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
EP0814833B1 (en) 1995-03-22 2003-05-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US20030157129A1 (en) 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
JP2004505885A (ja) 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DE10012370A1 (de) 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
KR100898845B1 (ko) 2000-06-29 2009-05-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 다가 백신 조성물
US6673905B2 (en) 2000-08-09 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Conjugation of biomolecules using Diels-Alder cycloaddition
YU66103A (sh) * 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
ES2318117T3 (es) 2002-03-26 2009-05-01 Novartis Vaccines And Diagnostics S.R.L. Sacaridos modificados que tienen una estabilidad mejorada en agua.
AU2002309259A1 (en) 2002-05-09 2003-11-11 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
AU2003299501A1 (en) 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
ATE352316T1 (de) 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
JP4827726B2 (ja) 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群に対する注射可能ワクチン
BRPI0410341B8 (pt) 2003-05-07 2021-05-25 Sanofi Pasteur Inc conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
US6933137B2 (en) 2003-05-16 2005-08-23 Aventis Pasteur Animal component free meningococcal polysaccharide fermentation and seedbank development
MXPA05014015A (es) 2003-06-23 2006-03-17 Baxter Int Vacunas contra grupo y nisseria meningitidis y combinaciones meningococales del mismo.
ATE414535T1 (de) 2003-06-23 2008-12-15 Baxter Int Trägerproteine für impfstoffe
CA2948114C (en) 2003-08-06 2019-02-26 Che-Hung Robert Lee Polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
CU23236A1 (es) 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1776389B1 (en) 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
WO2006026689A2 (en) 2004-08-30 2006-03-09 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
AU2005286798A1 (en) 2004-09-21 2006-03-30 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2006042542A2 (en) 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US8062641B2 (en) 2005-05-06 2011-11-22 Novartis Ag Immunogens for meningitidis-A vaccines
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
KR101359953B1 (ko) 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0513071D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
ES2443529T3 (es) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
CA2621578C (en) 2005-09-05 2014-07-22 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
BRPI0516372A (pt) 2005-12-22 2008-09-02 Sanofi Pasteur Inc conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina
DK2384765T3 (en) 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
JP5286089B2 (ja) 2006-01-13 2013-09-11 バクスター・インターナショナル・インコーポレイテッド ポリサッカライドを精製する方法
KR20150038626A (ko) 2006-03-17 2015-04-08 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
TR201807355T4 (tr) 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa Meningokokkal konjugatlarla immünizasyon rejimleri.
CU23575A1 (es) 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
CU23572A1 (es) 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20090123499A1 (en) 2006-06-12 2009-05-14 Nathalie Devos Vaccine
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
MX2009001412A (es) 2006-08-07 2009-04-24 Harvard College Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008129559A2 (en) 2007-04-23 2008-10-30 Serum Institute Of India Ltd Antigenic polysaccharides and process for their preparation
WO2008149238A2 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
WO2008157590A1 (en) 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
EP2173759A4 (en) 2007-07-03 2014-01-29 Childrens Hosp & Res Ct Oak OLIGOSIAL INSERTS, PROCESS FOR THEIR PREPARATION AND ITS IMMUNOLOGICAL USE
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
EP2462949A3 (en) 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
EP2254594B1 (en) 2008-03-05 2015-06-03 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
GB0810894D0 (en) 2008-06-13 2008-07-23 Novartis Vaccines & Diagnostic Conjugated saccharide
KR101573648B1 (ko) 2008-07-21 2015-12-01 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US9358302B2 (en) 2009-03-23 2016-06-07 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2585106A1 (en) * 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
US9120848B2 (en) 2010-09-23 2015-09-01 Harvey Kaplan Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
ES2728653T3 (es) 2011-05-18 2019-10-28 Matrivax Inc Composiciones vacunales con una matriz proteica que incluye policationes
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
IN2012MU00206A (OSRAM) * 2012-01-20 2013-08-09
SG11201404447WA (en) * 2012-01-30 2014-08-28 Serum Inst India Ltd Immunogenic composition
PE20190458A1 (es) 2012-03-09 2019-04-01 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
CN104428008B (zh) 2012-05-24 2020-10-09 美国政府(由卫生和人类服务部的部长所代表) 多价脑膜炎球菌缀合物及制备缀合物的方法
MX2014014649A (es) 2012-05-30 2015-08-06 Brigham & Womens Hospital Composiciones de polisacáridos y métodos de uso.
WO2014009971A2 (en) 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
EP3421051B1 (en) 2012-08-16 2020-05-13 Pfizer Inc Glycoconjugation processes and compositions
CN102809656B (zh) 2012-08-26 2014-09-03 云南沃森生物技术股份有限公司 一种脑膜炎球菌多糖结合疫苗成品各群游离多糖含量的测定方法
AU2013311702A1 (en) * 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
BR112015007126A2 (pt) 2012-10-02 2017-08-08 Glaxosmithkline Biologicals Sa composição, método para induzir uma resposta imune, e, uso de uma composição
BR112015011722B1 (pt) 2012-11-21 2022-08-09 Serum Institute Of India Ltd Método para preparar um polissacarídeo capsular de neisseria meningitidis x
SI2935299T1 (sl) 2012-12-20 2019-12-31 Pfizer Inc. Postopek glikokonjugacije
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
MX382165B (es) 2013-03-18 2025-03-13 Glaxosmithkline Biologicals Sa Una vacuna conjugada contra n. meningitidis para usarse en la prevención o tratamiento de enfermedades por n. meningitidis.
WO2014188313A1 (en) 2013-05-20 2014-11-27 Shantha Biotechnics Limited Purification of polysaccharide protein conjugates
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP6739333B2 (ja) 2013-07-11 2020-08-12 ノバルティス アーゲー 部位特異的化学酵素的タンパク質修飾
CN105636608A (zh) 2013-10-11 2016-06-01 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 免疫原性增强的多糖-蛋白质缀合物及其快速高产的制备方法
US10378017B2 (en) 2013-12-02 2019-08-13 Brandeis University High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
EP3443983B1 (en) 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
MY186874A (en) 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
CA2939887A1 (en) 2014-02-25 2015-09-03 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd. Novel oligomers and process of preparing thereof
EP3131576B1 (en) 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
CN104069504B (zh) 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
US10420833B2 (en) 2014-05-19 2019-09-24 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
US20170198004A1 (en) 2014-05-24 2017-07-13 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
SG11201702451WA (en) * 2014-10-09 2017-04-27 Msd Wellcome Trust Hilleman Lab Pvt Ltd An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof
MX391027B (es) 2015-02-19 2025-03-21 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
EP3288983B1 (en) 2015-04-28 2025-10-29 Biological E Limited Method for separation of protein and other impurities from microbial capsular polysaccharides
CN104998255B (zh) 2015-06-30 2018-08-28 北京祥瑞生物制品有限公司 新型acyw135群脑膜炎球菌结合疫苗及其制备方法
US10543266B2 (en) 2015-07-04 2020-01-28 Bharat Biotech International Ltd. Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
CN105061629A (zh) 2015-08-31 2015-11-18 成都欧林生物科技股份有限公司 A群脑膜炎球菌荚膜粗多糖纯化工艺
HK1259103A1 (zh) 2015-11-17 2019-11-22 Pfizer Inc. 用於在细菌细胞培养物中生产多糖的培养基和发酵方法
KR102428253B1 (ko) 2016-03-15 2022-08-02 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 신규한 다당류-단백질 접합체 및 이의 제조방법
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
EP3585427A4 (en) 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS

Also Published As

Publication number Publication date
US11147866B2 (en) 2021-10-19
KR102692762B1 (ko) 2024-08-08
US20250152693A1 (en) 2025-05-15
CN109890413A (zh) 2019-06-14
JP7028932B2 (ja) 2022-03-02
ZA201901402B (en) 2024-06-26
SI3506935T1 (sl) 2024-06-28
US20190175718A1 (en) 2019-06-13
BR112019003992A2 (pt) 2019-05-28
KR20230135178A (ko) 2023-09-22
JP7329087B2 (ja) 2023-08-17
HUE066007T2 (hu) 2024-07-28
JP2021001182A (ja) 2021-01-07
MX2019002489A (es) 2019-10-21
US20210401964A1 (en) 2021-12-30
EP3506935B1 (en) 2024-01-10
CA3033364A1 (en) 2018-03-08
CN118236477B (zh) 2025-04-25
EP3506935A1 (en) 2019-07-10
US20230310567A1 (en) 2023-10-05
ES2974992T3 (es) 2024-07-02
RS65362B1 (sr) 2024-04-30
PH12019500399A1 (en) 2019-05-20
CN109890413B (zh) 2024-04-16
CN118236477A (zh) 2024-06-25
LT3506935T (lt) 2024-04-25
US11707514B2 (en) 2023-07-25
SA519401227B1 (ar) 2022-02-28
DK3506935T3 (en) 2024-04-02
AU2024223993A1 (en) 2024-10-24
PT3506935T (pt) 2024-04-01
HRP20240433T1 (hr) 2024-07-05
EP4309670A3 (en) 2024-07-17
JP2019526573A (ja) 2019-09-19
EP4309670A2 (en) 2024-01-24
PL3506935T3 (pl) 2024-06-10
FI3506935T3 (fi) 2024-04-17
AU2017321863B2 (en) 2024-07-11
JP2022065099A (ja) 2022-04-26
PH12019500399B1 (en) 2024-05-15
KR20190044663A (ko) 2019-04-30
WO2018045286A1 (en) 2018-03-08
SG11201901394XA (en) 2019-03-28
AU2017321863A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
JP7028932B2 (ja) ナイセリア・メニンギティディスのワクチン
AU2018225099B2 (en) Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
EP3576784B1 (en) Methods for making polysaccharide-protein conjugates
AU2016295566B2 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3576759B1 (en) Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
KR102486891B1 (ko) 다가 폐렴구균성 다당류-단백질 접합체 조성물
JP6808658B2 (ja) 多価肺炎球菌コンジュゲートワクチン
JP2020533437A (ja) 肺炎球菌多糖体および免疫原性多糖体−キャリアタンパク質コンジュゲートでのその使用
JP2025084846A (ja) 免疫原性血清型３５ｂ肺炎球菌多糖類－タンパク質コンジュゲート及びそれを作成するためのコンジュゲーションプロセス
HK40005680A (en) Neisseria meningitidis vaccine
HK40005680B (en) Neisseria meningitidis vaccine
EA040960B1 (ru) Вакцина против neisseria meningitidis
US20220031829A1 (en) Combined immunization against meningococcal disease and human papillomavirus
HK1195512A1 (zh) 多糖-蛋白轭合物疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200331

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200331

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200910

R150 Certificate of patent or registration of utility model

Ref document number: 6764021

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250